Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

Which Antipsoriatic Drug Has the Fastest Onset of Action?—Systematic Review on the Rapidity of the Onset of Action

(2013) Alexander Nast et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis

(2013) Eleanor J. Samarasekera et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis

(2013) U. Mrowietz et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study

(2012) S. Dogra et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment

(2012) T.C. Lucka et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) B.E. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

(2011) J. Barker et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

(2011) Jerry Bagel et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Definition of treatment goals for moderate to severe psoriasis: a European consensus

(2010) U. Mrowietz et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial

(2010) S. Fallah Arani et al.   BRITISH JOURNAL OF DERMATOLOGY

The Impact of Methodological Approaches for Presenting Long-Term Clinical Data on Estimates of Efficacy in Psoriasis Illustrated by Three-Year Treatment Data on Infliximab

(2010) M. Papoutsaki et al.   DERMATOLOGY

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

(2010) Hideshi Torii et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

Comparing biological therapies in psoriasis: implications for clinical practice

(2010) CEM Griffiths   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

(2010) David Moher et al.   International Journal of Surgery

Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life

(2009) S. G. Y. Ho et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Complexity of the Association Between Psoriasis and Comorbidities

(2009) Tamar Nijsten et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review

(2009) Phyllis I. Spuls et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

(2009) D Pathirana et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial

(2008) P. Gisondi et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

(2008) J. Schmitt et al.   BRITISH JOURNAL OF DERMATOLOGY

Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial

(2008) M. Caproni et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY